The Clinical Research Of The Recombinant Adenovirus P53 Combination With Radiotherapy In Treatment Of Nasopharyngeal Carcinoma

Objective: To evaluate the effect of recombinant adenovirus P53 agent combined with radiotherapy in treatment of nasopharyngeal carcinoma and toxic side effect that might appear to treat nasopharyngeal carcinoma.Methods: We selected 16 cases samples of original III, IV phase in nasopharyngeal carcinoma which had already been confirmed by pathology department of the first affiliated hospital in Anhui Medical University, there was no statistics meaning (P> 0.05) to two groups of sex, age, size of tumor, radiation field and radiotherapy dosage in the harmony test. 16 cases with nasopharyngeal carcinoma were divided randomly into two groups: the both gene therapy+radiotherapy group (treatment group) and single radiotherapy (control group) 8 for 8. As for treatment group: every Friday, 1ml of rAd-p53 is injected, at the beginning of the week , we adopt united field of the face and neck, 2 Gy every day, 5 days continuously and totally 6 weeks. rAd-p53 was produced by Bainuo Gene technological Co., Ltd., specification: 1*1012 VP each one. When used the medicine, we firstly took one out from the refrigerator of 20 degrees below zero and waited another half an hour after it melted inside the room. adopted injection inside the tumor under the guide of the nasal sinus endoscope. If the diameter of the tumor was less than 4cm, it was diluted to 2ml with the physiological saline before it was used; if the diameter was more than 4cm, it was diluted to 4ml. Each time we inject the tumor body, we take pictures to make comparison by itself. Control group: united field of the face and neck conventional radiotherapy continued 5 days a week and 2Gy a day and totally 6 weeks. Three days before the treatment, a week after the treatment and also a month after the treatment, the two groups were given blood routine, urine routine, hepatic function, renal function and electrocardiogram to check separately. Three days before the treatment and also a month after the treatment, both the groups were given the nasopharynx CT inspection separately. The pharynx nasalis dosage of two groups was 70 Gy/35 times, dosage of lymph nodes in cervical part was 60 Gy/30 times.Results: 1. Two groups were both given the nasopharynx CT inspection, a month after the treatmnet, the tumor body of the control group diden't shrink obviously, compared to before treatment.2. As for the treatment group, a month after the treatment, the tumor body of the control group shrank obviously, compared to before treatment.3. By self-comparison, the tumor body shrank obviously before and after the treatment and the difference had statistics meaning (P<0.05).4. As for the treatment group, the relative index of blood routine, routine urine test, hepatic function and renal function before and after treatment had no statistics meaning and there was no obvious abnormity.5.There was no other side effects except the self-limited fever.6 difference of emotion condition had statistics meaning between treatment group and control group(P<0.05). the others had no statistics meaning in basical conditon(P>0.05).Conclusion: 1. The unite radiotherapy of rAd-p53 to treat nasopharyngeal carcinoma is quite effective.2.It is safe to treat nasopharyngeal carcinoma by unite radiotherapy of rAd-p53 and the patients who have side effects can tolerate.